What is the recommended management for a suspected Ebola virus disease case in 2026?

Suspected Ebola Virus Disease (EVD) in 2026: Immediate Management

Boldly isolate the patient now with full-contact and droplet precautions in a designated high-level isolation setting, obtain Ebola rRT-PCR urgently, and if Zaire ebolavirus is confirmed, administer FDA‑approved REGN‑EB3 (Inmazeb) as early as possible to reduce mortality; provide aggressive supportive care regardless of species. 1

1) Trigger for Action (who to isolate/test immediately)

• Symptoms: fever, severe headache, myalgias, vomiting/diarrhea, abdominal pain, unexplained bleeding.
• Epidemiology within 21 days: travel/residence in an affected area or contact with a known/probable EVD/Bundibugyo case, funeral exposure, or HCW exposure. Prior Ervebo vaccination does not exclude disease. 2, 1

2) Infection prevention and control (protect staff; prevent spread)

• Place in single room within a high-level isolation unit (HLIU) if available; otherwise, immediately implement high-level barrier nursing with trained observers for donning/doffing. 3
• PPE: impermeable gown/coverall, double gloves, boot/leg covers, head/neck coverage, eye/face protection (face shield) plus fit-tested N95 or higher; consider PAPR for high-risk aerosol-generating procedures, recognizing cleaning/functional pitfalls. 3
• Minimize procedures/transport; perform bedside imaging and dialysis with dedicated equipment; decontaminate all waste as infectious. Limit phlebotomy to essential tests. 3
• Manage cardiac arrest/intubation only if necessary with maximal precautions due to high exposure risk. 3

3) Diagnostic algorithm (confirm while maintaining isolation)

• Order EBOV/ebolavirus rRT-PCR urgently (specimen per public health lab guidance). Keep patient isolated until two negative PCRs if high suspicion. If first PCR is negative within <72 hours of symptom onset, repeat after 24–48 hours. 4
• Differentiate species (Zaire vs Bundibugyo vs others) because it determines availability of specific therapy and vaccine relevance. 5, 6, 7

4) Therapeutics prioritized by mortality benefit

• If species is Zaire ebolavirus:
  • Start monoclonal antibody therapy immediately upon confirmation:
    • REGN‑EB3 (Inmazeb) is FDA‑approved and superior to control for mortality; earlier treatment reduces deaths. Dose per label; treat adults and pediatrics. 1
  • Continue aggressive supportive care (IV fluids, electrolytes, nutrition) which independently reduces mortality. 1
• If species is Bundibugyo virus (BDBV):
  • No FDA‑approved MAb; use maximal supportive care and consult trial/expanded-access options. Remdesivir has been used case-by-case with recovery reported but without definitive mortality evidence; prioritize clinical trials if available. 5, 7
• For all species:
  • Early hemodynamic optimization, renal support if needed (bedside/dedicated machines), correction of electrolytes/coagulopathy, antiemetics, pain control, and careful glucose management improve survival and quality of life. 3, 1
• Avoid delays: each day’s delay in treatment increases odds of death. 1

5) Public health actions (containment and risk reduction)

• Immediately notify local/state/national public health authorities for coordination, testing logistics, and transport to designated Ebola treatment centers. 1
• Initiate exposure-based contact identification, risk-stratified monitoring of contacts, and rapid isolation of any symptomatic contacts; ring strategies and focused monitoring are preferred over routine border screening. 2

6) Vaccination (pre-exposure for high-risk workers; not for acute treatment)

• Ervebo (rVSV‑ZEBOV‑GP) is FDA‑licensed for prevention of Zaire ebolavirus; give as a single 1‑mL IM dose to adults ≥18 at highest occupational risk (outbreak responders, HLIU personnel, BSL‑4 staff). Store/administer exactly per cold-chain and label guidance. This is prevention, not treatment. 1
• Note: Ervebo targets Zaire; cross‑protection for Bundibugyo is uncertain. Do not rely on vaccine status to rule out disease. 1, 7

7) Special populations and persistence risks

• Survivors may have viral persistence (e.g., CSF, breast milk) with potential late relapse or transmission; follow survivorship and body-fluid management protocols. Breastfeeding can transmit EBOV; manage with expert guidance. 1

8) Common pitfalls to avoid

• Do not delay isolation while “confirming” history.
• Do not remove PPE without supervision; most HCW exposures occur during doffing. 6
• Do not transport the patient for imaging/dialysis; bring equipment to bedside and dedicate it. 3
• Do not withhold REGN‑EB3 when Zaire ebolavirus is confirmed; it reduces mortality and benefit is time‑sensitive. 1
• Do not assume border screening is protective; use risk-based monitoring and rapid isolation. 2

9) If resources are austere or conflict-affected

• Implement a pragmatic IPC bundle: reliable PPE supply, competency‑based training with supervised doffing, cohorting and one‑way flow, environmental controls, and staffing plans; treat these as interdependent to reduce HCW mortality and nosocomial spread. 6

10) U.S. context, 2026 risk

• Community risk is low but consequences are high; maintain readiness at designated centers and follow ACIP vaccination guidance for high‑risk workers. 8, 1